Clinical and Prognostic Implications of P21 (WAF1/CIP1) Expression in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis

Table 3

Main results for meta-analysis between p21 and clinicopathological features in esophageal cancer.

Clinical parameters	OR [95% CI]					Begg’s test
Tissue	2.210 [0.811-6.022]	0.121	1.550	90.9%		0.373
Age	0.969 [0.716-1.312]	0.840	0.210	81.8%		0.732
Gender	0.758 [0.566-1.015]	0.063	1.860	85.4%		0.484
Differentiation	2.153 [1.455-3.184]		3.840	41.3%	0.023	0.185
Clinical stage	1.616 [1.068-2.446]	0.023	0.002	53.4%	0.002	0.096
Tumor stage	0.885 [0.541-1.448]	0.627	0.490	93.7%		0.089
Lymph node	1.691 [1.165-2.455]	0.006	2.760	57.7%		1.000
Metastasis	0.637 [0.356-1.140]	0.129	1.520	76.7%		0.296
Grading	3.399 [2.278-5.071]		5.990	31.0%	0.170	0.532
Invasion	1.939 [1.328-2.830]	0.001	3.430	58.9%		0.788
Tumor size	1.005 [0.602-1.675]	0.986	0.020	36.0%	0.181	0.806
Tumor location	0.971 [0.553-1.706]	0.918	0.100	51.8%	0.034	0.917
P53	1.700 [0.918-3.148]	0.092	1.690	63.6%	0.003	0.210
AI (apoptosis index)	0.131 [0.064-0.269]		5.550	65.6%		1.000
Chemotherapy effectivity	5.987 [2.930-12.234]		4.910	44.3%		0.462

OR = odds ratio; CI = confidence interval.